Trial of Nivolumab Following Partially Human Leukocyte Antigen (HLA) Mismatched BMT in Children & Adults With Sarcoma
NCT03465592
Recruiting
This research is being done to find out if an investigational drug, Nivolumab, can be safely administered after a "half-matched" (haplo) bone marrow transplant (BMT), and if the investigational drug will help to prevent or delay relapse or progression of sarcomas. In this study investigators will also be trying to learn more about how the investigational drug changes blood and/or tumors. Participants are eligible for this trial if they have recently undergone a "half-matched" (haplo) bone marrow... Read More
Gender:
ALL
Ages:
Between 12 months and 40 years
Trial Updated:
02/05/2025
Locations: Johns Hopkins All Children's Hospital, Saint Petersburg, Florida +3 locations
Conditions: Sarcoma, Solid Tumor, Adult, Solid Tumor, Childhood
Register for Updates
Engaging Native Hawaiian/Pacific Islanders and Activating Communities to Take Steps (ENACTS)
NCT03484364
Recruiting
Our Specific Aims are: 1. At the individual level, to compare within-person change in BP and secondary outcomes between the intervention and control groups. 2. At the family level, to evaluate ENACTS' effects on BP and secondary outcomes as within-person change in family members who provide primary support, and as mean change in other adult family members who are not directly engaged in the intervention. 3. At the policy level, to evaluate the intervention's ability to influence grocery store p... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/05/2025
Locations: National Recruitment via Facebook and Internet, Seattle, Washington
Conditions: Hypertension
Register for Updates
Long-term, Substantial Weight Loss and Insulin Regulation of Lipolysis
NCT03868592
Recruiting
It is not known how much improvement in insulin regulated lipolysis (the breakdown of triglycerides) occurs following substantial, sustained weight loss. Researchers will test the effects of inflammation and lipolysis regulation in people before and after bariatric surgery (sleeve gastrectomy) to answer these questions.
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
02/05/2025
Locations: Mayo Clinic, Rochester, Minnesota
Conditions: Obesity, Morbid
Register for Updates
Anticoagulation for New-Onset Post-Operative Atrial Fibrillation After CABG
NCT04045665
Recruiting
The primary objective of this study is to evaluate the effectiveness (prevention of thromboembolic events) and safety (major bleeding) of adding oral anticoagulation (OAC) to background antiplatelet therapy in patients who develop new-onset post-operative atrial fibrillation (POAF) after isolated coronary artery bypass graft (CABG) surgery. All patients with a qualifying POAF event, who decline randomization, will be offered the option of enrollment in a parallel registry that captures their ba... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/05/2025
Locations: CHI St. Vincent, Arkansas, Little Rock, Arkansas +95 locations
Conditions: Atrial Fibrillation, Stroke, Bleeding
Register for Updates
Trial to Evaluate and Assess the Effect of Comprehensive Pre-ESKD Education on Home Dialysis Use in Veterans
NCT04064086
Recruiting
This study is intended to correct an important systemic deficit in the care of chronic kidney disease (CKD), VHA's fourth most common healthcare condition with high mortality and healthcare burden. Currently, many Veterans with CKD have poor awareness of their condition. This leads to suboptimal care. The investigators anticipate that the proposed comprehensive pre-end stage renal disease (ESRD) education (CPE) will enhance Veterans' CKD knowledge and their confidence in making an informed selec... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/05/2025
Locations: North Florida/South Georgia Veterans Health System, Gainesville, FL, Gainesville, Florida
Conditions: Chronic Kidney Disease, End Stage Renal Disease, Hemodialysis, Peritoneal Dialysis
Register for Updates
Using Radiogenomics to Predict Malignant Potential of Intraductal Papillary Mucinous Neoplasms of the Pancreas
NCT04275557
Recruiting
The Florida Pancreas Collaborative wants to partner with individuals who are known to have, or are suspected to have a pancreatic lesion, tumor, cyst, mass, cancer, or pancreatitis and are undergoing diagnosis and treatment at a participating institution. The goals of this project are to build a large database of information obtained from blood, tissue, medical images, surveys and information from routine care to develop noninvasive diagnostic approaches that could be used as decision-making too... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/05/2025
Locations: Florida Research Institute (FRI), Lakewood Ranch, Florida +2 locations
Conditions: Pancreatic Cancer, Pancreatic Cyst
Register for Updates
Physiologic MR Imaging of Salivary Gland Tumors
NCT04452162
Recruiting
The goal of this study is to use advanced Magnetic Resonance Imaging (MRI) techniques to help identify the difference between cancerous and non-cancerous salivary gland tumors for improving treatment strategies and to aid in the prediction of disease progression.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/05/2025
Locations: Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania
Conditions: Salivary Gland Tumor
Register for Updates
Bioenergetic Phenotypes and Cardiometabolic Health
NCT04427462
Recruiting
This research study is about how daily activities, behaviors, and fitness affect the health and function of blood cells and their mitochondria, which are the powerhouses of the cells. These small mitochondria inside the cells make energy, and are very important for the health of the body.
Gender:
ALL
Ages:
Between 8 years and 10 years
Trial Updated:
02/05/2025
Locations: Arkansas Children's Nutrition Center, Little Rock, Arkansas
Conditions: Healthy
Register for Updates
Anti-CD19 Chimeric Antigen Receptor T Cells for Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma
NCT04545762
Recruiting
This study will assess safety and feasibility of infusing genetically modified autologous T cells transduced to express a chimeric antigen receptor targeting the B cell surface antigen Cluster of Differentiation 19 (CD19)
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/05/2025
Locations: University of California, San Francisco, San Francisco, California
Conditions: Refractory Non-Hodgkin Lymphoma, Burkitt Lymphoma, Mantle Cell Lymphoma, Follicular Lymphoma, Lymphoplasmacytic Lymphoma, Primary Mediastinal Large B Cell Lymphoma, Diffuse Large B Cell Lymphoma, Small Lymphocytic Lymphoma, Transformed Lymphoma
Register for Updates
Access to Kidney Transplantation in Minority Populations
NCT04615819
Recruiting
Hispanic/Latino (HL) and American Indian (AI) patients are more likely than whites to have kidney failure, but less likely to complete transplant evaluation or receive a kidney transplant (KT), the best treatment for kidney failure. Using comparative effectiveness research methods, we will conduct a pragmatic randomized trial to compare the efficacy and cost- effectiveness of two approaches to help HL and AI patients overcome barriers to completing transplant evaluation and receiving a KT: a str... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/05/2025
Locations: University of New Mexico, Albuquerque, New Mexico
Conditions: Kidney Diseases
Register for Updates
The Effects of SCFA Supplementation in Subjects Receiving Abdominopelvic RT: A Randomized Controlled Study
NCT04700527
Recruiting
The purpose of this study is to assess and compare GI toxicity from RT between subjects who receive therapeutic SCFA and those who receive placebo, in hopes of identifying a safe, low-cost therapeutic to reduce GI toxicity from therapeutic or environmental radiation.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/05/2025
Locations: Flora Danquah, Chapel Hill, North Carolina
Conditions: Toxicity, Radiation Toxicity
Register for Updates
Isatuximab, Pomalidomide, Elotuzumab and Dexamethasone in Relapsed And/or Refractory Multiple Myeloma
NCT04835129
Recruiting
This is a multicenter, open-label phase II study in subjects with relapsed and/or refractory multiple myeloma with at least two prior lines of therapy. The main study consists of three phases: a 28-day screening phase, treatment phase that consists of 28-day cycles of isatuximab with elotuzumab, pomalidomide, and dexamethasone and a follow-up phase.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/05/2025
Locations: The University of Alabama at Birmingham, Birmingham, Alabama +1 locations
Conditions: Multiple Myeloma
Register for Updates